Christopher J Record,Mariola Skorupinska,Matilde Laura,Alexander M Rossor,Davide Pareyson,Chiara Pisciotta,Shawna M E Feely,Thomas E Lloyd,Rita Horvath,Reza Sadjadi,David N Herrmann,Jun Li,David Walk,Sabrina W Yum,Richard A Lewis,John Day,Joshua Burns,Richard S Finkel,Mario A Saporta,Sindhu Ramchandren,Michael D Weiss,Gyula Acsadi,Vera Fridman,Francesco Muntoni,Roy Poh,James M Polke,Stephan Zuchner,Michael E Shy,Steven S Scherer,Mary M Reilly,Lisa Abreu,Kimberly A Anderson,Silvia Baratta,Debbie Berry,Julian Blake,Eleonora Cavalca,Kayla Cornett,Andrea Cortese,Gabrielle Donlevy,Amanda Dragon,Magdalena Dudziec,Katy Eichinger Tim Estilow,Valerie Ferment,Natalie Grant,Tiffany Grider,Emily Hyslop,Tara Jones,Nicole Kressin,Wendy Leon,Stefania Magri,Brett McCray,Manoj Menezes,Evelin Milev,Lindsey Parrott,Pooja Patel,Cláudia Brito Pires,Valeria Prada,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary Shy,Carly Siskind,Janet Sowden,Sydney Stork,Charlotte J Sumner,Franco Taroni,Simone Thomas,Jennifer Twachtman-Bassett,Nidia Villalpando,Dragan Vujovic,Julie Wells,Elizabeth Wood,Riccardo Zuccarino,for the Inherited Neuropathies Consortium - Rare Disease Clinical Research Network

Abstract:Charcot-Marie-Tooth disease (CMT) due to GJB1 variants (CMTX1) is the second most common form of CMT. It is an X-linked disorder characterised by progressive sensory and motor neuropathy with males affected more severely than females. Many reported GJB1 variants remain classified as variants of uncertain significance (VUS). In this large, international, multicentre study we prospectively collected demographic, clinical and genetic data on patients with CMT associated with GJB1 variants. Pathogenicity for each variant was defined using adapted American College of Medical Genetics criteria. Baseline and longitudinal analyses were conducted to study genotype-phenotype correlations, to calculate longitudinal change using the CMT Examination Score (CMTES), to compare males versus females, and pathogenic/likely pathogenic (P/LP) variants versus VUS. We present 387 patients from 295 families harbouring 154 variants in GJB1 . Of these, 319 patients (82.4%) were deemed to have P/LP variants, 65 had VUS (16.8%) and 3 benign variants (0.8%; excluded from analysis); an increased proportion of patients with P/LP variants compared with using ClinVar's classification (74.6%). Male patients (166/319, 52.0%, P/LP only) were more severely affected at baseline. Baseline measures in patients with P/LP variants and VUS showed no significant differences, and regression analysis suggested the disease groups were near identical at baseline. Genotype-phenotype analysis suggested c.-17G>A produces the most severe phenotype of the five most common variants, and missense variants in the intracellular domain are less severe than other domains. Progression of disease was seen with increasing CMTES over time up to 8 years follow-up. Standard response mean (SRM), a measure of outcome responsiveness, peaked at 3 years with moderate responsiveness (change in CMTES (ΔCMTES) = 1.3 ± 2.6, p = 0.00016, SRM = 0.50). Males and females progressed similarly up to 8 years, but baseline regression analysis suggested that over a longer period, females progress more slowly. Progression was most pronounced for mild phenotypes (CMTES = 0-7; 3-year ΔCMTES = 2.3 ± 2.5, p = 0.001, SRM = 0.90). Enhanced variant interpretation has yielded an increased proportion of GJB1 variants classified as P/LP and will aid future variant interpretation in this gene. Baseline and longitudinal analysis of this large cohort of CMTX1 patients describes the natural history of the disease including the rate of progression; CMTES showed moderate responsiveness for the whole group at 3 years and higher responsiveness for the mild group at 3, 4 and 5 years. These results have implications for patient selection for upcoming clinical trials.

CNS Involvement in CMTX1 Caused by a Novel Connexin 32 Mutation: a 6-Year Follow-Up in Neuroimaging and Nerve Conduction

[A Genotyping Study of 13 Cases of Early-Onset Charcot-Marie-Tooth Disease].

[A New Mutation in the Connexin 32 Gene of a Chinese Family with Charcot-Marie-Tooth Disease Associated with Central Conduction Slowing].

Episodic Neurological Dysfunction in X-Linked Charcot-Marie-Tooth Disease: Expansion of the Phenotypic and Genetic Spectrum

Unusual features of central nervous system involvement in CMTX associated with a novel mutation of GJB1 gene

Analysis of the clinical, electrophysiological and histopathological features of Chinese Charcot-Marie Tooth disease patients with small heat-shock protein 27 gene mutation

Mutation Screening of Cx32 in Han Chinese Patients with Charcot-Marie-Tooth Disease.

Cx32 Gene Mutation Associated with X-linked Recessive Charcot-Marie-Tooth Disease

Transient White Matter Lesions in X-linked Charcot-Marie-Tooth Disease Type 1 with Novel I20T Mutation of Gap Junction Protein Beta 1 Gene

Author Response for "genetic Spectrum and Clinical Profiles in a Southeast Chinese Cohort of Charcot‐Marie‐Tooth Disease"

A Novel Mutation of LRSAM1 in a Chinese Family with Charcot-Marie-Tooth Disease

Clinical and Genetic Characteristics of Charcot-Marie-Tooth Disease

Clinical and Genetic Features of Chinese X-Linked Charcot-Marie-Tooth Type 1 Disease

[Episodic Central Nervous System Symptoms with Reversible White Matter Involvement in Chinese Patients with X-linked Charcot-Marie-Tooth Disease and Literatures Review].

A New Locus for Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 (CMT2L) Maps to Chromosome 12Q24

[Analysis of the Pathological Features and Gene Mutations of Chinese Patients with Charcot-Marie-Tooth Disease].

A novel mutation of gap junction protein beta 1 gene in X-linked Charcot-Marie-Tooth disease

Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants

Two Novel Mutations of GJB1 Gene Associated with Typical X-linked Charcot-Marie-Tooth Disease

Pathologic and Genetic Features in 6 Chinese X-linked Charcot-Marie-Tooth Disease Type 1 Families